Polidocanol API Manufacturers

Looking for Polidocanol API 9002-92-0?

Description:

Here you will find a list of producers, manufacturers and distributors of Polidocanol. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Polidocanol 

Synonyms:

Laureth 9 , Aethoxy-sklerol , Laureth-9 , Macrogol 9 lauryl ether , Nonaethylene glycol monododecyl ether , Nonaethylene glycol monolauryl ether , PEG-9 lauryl ether , Polydocanol , Polyethylene glycol 450 lauryl ether , Polyoxyl 9 lauryl ether , Macrogol Lauryl Ether 9  

Cas Number:

9002-92-0 

DrugBank number:

DB06811 

Unique Ingredient Identifier:

ELB3Y6474W

Polidocanol is a type of Sclerosing agents

Sclerosing agents are a vital subcategory of pharmaceutical active pharmaceutical ingredients (APIs) used in various medical procedures. These agents are specifically formulated to induce sclerosis, a controlled and localized inflammatory response that leads to the formation of scar tissue. The primary purpose of sclerosing agents is to treat a wide range of medical conditions, including vascular malformations, varicose veins, hemorrhoids, and certain types of cysts.

Sclerosing agents work by causing irritation and inflammation at the target site, which triggers a series of biochemical reactions resulting in the formation of fibrous tissue. This fibrosis helps to close or shrink the affected blood vessels or abnormal growths, effectively addressing the underlying condition.

One commonly used sclerosing agent is polidocanol, a non-ionic detergent that acts by disrupting the endothelial lining of blood vessels, leading to thrombus formation and subsequent fibrosis. Another widely employed agent is sodium tetradecyl sulfate, which shares a similar mechanism of action. These agents are typically administered through injection directly into the affected area under the supervision of a medical professional.

The choice of sclerosing agent depends on factors such as the specific medical condition being treated, the size and location of the affected area, and the patient's overall health. Prior to administration, thorough evaluation and diagnosis by a healthcare provider are necessary to determine the appropriate sclerosing agent and dosage for optimal outcomes.

In conclusion, sclerosing agents play a crucial role in the treatment of various medical conditions by inducing controlled inflammation and scar tissue formation. With their targeted approach and effectiveness, these pharmaceutical APIs offer patients a promising therapeutic option to manage their specific ailments.

Polidocanol (Sclerosing agents), classified under Central Nervous System Agents

Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.

CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.

The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.

Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.

• Caesar & Loretz GmbH (CAELO) from Germany, product country of origin Unknown

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.